ストックスクリーナーアプリを入手
19.27
1.17%
-0.205
Beta Bionics Inc (BBNX) 最新ニュース
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics - Benzinga
Beta Bionics (NASDAQ:BBNX) Now Covered by William Blair - MarketBeat
William Blair initiates Beta Bionics stock rating at Market Perform - Investing.com
Beta Bionics Investor Alert: Johnson Fistel Reviews Potential Claims for Shareholders - GlobeNewswire
Beta Bionics (NASDAQ:BBNX) Trading 4.7% HigherHere's Why - MarketBeat
Beta Bionics (BBNX) Q2 2026 Earnings Call Transcript - AOL.com
Farallon group discloses 595,000-share Beta Bionics (BBNX) stake in 13G/A - Stock Titan
BofA Securities Maintains Beta Bionics(BBNX.US) With Hold Rating, Raises Target Price to $18 - Moomoo
BofA Securities Adjusts Price Target on Beta Bionics to $18 From $15.50 - marketscreener.com
Beta Bionics, Inc. Stock 12‑Month Price Target Raised to $20.31, Implies 24% Upside - TradingView
BofA Securities Adjusts Beta Bionics Price Target to $18 From $15.50 - marketscreener.com
Beta Bionics (NASDAQ:BBNX) Shares Up 13.7%Should You Buy? - MarketBeat
Beta Bionics, Inc. (BBNX) Stock Analysis: 42% Potential Upside Amidst Innovative Diabetes Solutions - DirectorsTalk Interviews
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Lazard Asset Management LLC Buys New Holdings in Beta Bionics, Inc. $BBNX - MarketBeat
Beta Bionics (BBNX) Drops 4.6% to $13.9, Testing Key Support Near $13.21Fair Value Gap - Vinanet
Beta Bionics, Inc. (BBNX) Investigation: Bronstein, Gewirtz & Gro - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Beta Bionics, Inc. (NASDAQ:BBNX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Perceptive Advisors LLC Buys 240,000 Shares of Beta Bionics, Inc. $BBNX - MarketBeat
A Quick Look at Today's Ratings for Beta Bionics(BBNX.US), With a Forecast Between $15.5 to $30.4 - Moomoo
Truist Financial Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Piper Sandler Maintains Beta Bionics(BBNX.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance - The Manila Times
Earnings call transcript: Beta Bionics misses Q2 2026 EPS as sales rise 38% - Investing.com Canada
Beta Bionics Q2 Results: Sales rise 37.8% YoY to $32M, EPS beats - scanx.trade
UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating - marketscreener.com
Beta Bionics, Inc. $BBNX Shares Acquired by Eversept Partners LP - MarketBeat
Beta Bionics Inc (BBNX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Beta Bionics, Inc. Revenue Breakdown – NASDAQ:BBNX - TradingView
Beta Bionics Inc (BBNX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
BBNX Q1 2026 Earnings: Narrower Loss Surprises but Shares SlipEarnings Manipulation Risk - Vinanet
Beta Bionics (BBNX) Stock Fair Value Falls As Medtech Reset Tempers iLet And Mint Optimism - Yahoo Finance
Beta Bionics Inc (BBNX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Beta Bionics Inc (BBNX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Beta Bionics Inc (BBNX) Institutional Confidence - TradingKey
Beta Bionics Inc (BBNX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Beta Bionics (BBNX) sees 6.9% stake reported by Divisadero Street group - Stock Titan
BBNX|Beta Bionics Inc|Price:16.097|Chg%:+0.247 - TradingKey
BBNX|Beta Bionics Inc|Price:16.140|Chg%:+0.290 - TradingKey
Beta Bionics Inc (BBNX) Balance Sheet - TradingKey
BBNX Falls 1.74% as Beta Bionics Faces Profit-Taking Near Key SupportCatalyst Driven Stocks - Vinanet
BBNX|Beta Bionics Inc|Price:16.330|Chg%:+0.200 - TradingKey
Beta Bionics (BBNX) Edges Higher as Investors Eye Key Resistance LevelPercent Below MA - dars.gov.et
Beta Bionics Inc. (BBNX) Surges Over 2% as Bullish Momentum BuildsCall Flow Alert - Vinanet
BBNX Maintained by Goldman Sachs -- Price Target Raised to $19.0 - GuruFocus
Goldman Sachs Maintains Beta Bionics(BBNX.US) With Buy Rating, Raises Target Price to $19 - Moomoo
If You Invested $1,000 in Beta Bionics, Inc. (BBNX) - Stock Titan
Beta Bionics Price Target Raised to $22.00/Share From $18.00 by Truist Securities - Moomoo
Truist Raises Price Target on Beta Bionics to $22 From $18, Keeps Buy Rating - Moomoo
Beta Bionics Inc. (BBNX) Q1 2026 Earnings: Narrower‑than‑expected loss masks progress in pivotal pipelineManagement Guidance Update - dars.gov.et
BBNX Shareholder Alert: Robbins LLP Reminds Beta Bionics, Inc. Stockholders that it is Investigating the Company's Officers and Directors to Determine if They Violated Securities Laws and Breached Fiduciary Duties to Shareholders - AOL.com
Beta Bionics (BBNX) Edges Higher, Testing Key Resistance After Positive MomentumTRIN Signal - dars.gov.et
ETFs Investing in Beta Bionics, Inc. Stocks - TradingView
Price to earnings forward of Beta Bionics, Inc. – NASDAQ:BBNX - TradingView
Price to book forward of Beta Bionics, Inc. – NASDAQ:BBNX - TradingView
BBNX PE Ratio & Valuation, Is BBNX Overvalued - Intellectia AI
Beta Bionics CFO Stephen Feider sells $170k of BBNX stock By Investing.com - Investing.com South Africa
Beta Bionics CFO Stephen Feider sells $170k of BBNX stock - Investing.com
Form 4 Beta Bionics Inc For: 2 July By Investing.com - Investing.com Canada
CFO trades 10,000 Beta Bionics (BBNX) shares under Rule 10b5-1 plan - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Is Investigating Beta Bionics, Inc. (BBNX) And Encourages Investors to Connect - The National Law Review
1.38%
0.31%
大文字化:
|
ボリューム (24 時間):